Empowering Healthier Lives

We believe that fast, accurate point of care testing empowers people to enjoy healthier, more informed lives.

Consumers are embracing the power of at-home diagnostics and telehealth.

The Opportunity

This is a pivotal moment in healthcare. Increased consumer acceptance of telemedicine and the need for faster information has generated even greater demand for rapid point of care diagnostics.

Atomo has developed the most consumer friendly platform available for rapid at-home testing. Our integrated testing technology helps revolutionize access to healthcare solutions and deliver improved healthcare outcomes. We are a world leader in rapid testing solution that puts the user in the center of the testing experience.

Our technology, which is easy to use, safe, reliable, and intuitive, is uniquely positioned to support the growing demand for affordable point of care monitoring of health and at-home testing.

Our Story

After ten years as a senior leader in the medical device sector, Atomo’s Founder and CEO John Kelly identified multiple ways in which diagnostics were ripe for transformation. John observed that usability, convenience, and simplicity of use could make a real difference in diagnostics. When people can’t use a product the way it is intended, the performance is undermined.

While John was exploring areas of the market where usability was poorly delivered, his youngest daughter was born and required intensive medical care for the first two years of her life. He watched as doctors struggled to collect blood from her arm. When John found out that the blood test they were doing only required a tiny drop of blood, he had a light bulb moment. John decided to develop a better, less invasive way to collect a blood sample.

Vision & Mission

Empowering people to enjoy healthier, more informed lives through fast, accurate point of care testing. We are re-imagining diagnostics by putting the user experience at the center of everything we do. Atomo's mission is to ensure equitable and affordable access to accurate diagnoses and promote a seamless pathway to treatment.



Commercialising products that matter to our users


Fostering creative thinking and solutions


Ensuring honesty and fairness in all that we do


Working as one
global team


Being recognised as experts in the field

Executive Team

John Kelly

Founder, Managing Director & CEO

For more than 20 years John Kelly has championed the cause of reimagining medical devices to enhance their usability and performance. Before founding Atomo Diagnostics in 2010, John was Chief Operating Officer at ASX listed (now NASDAQ listed) Unilife Corporation, where he led the ‘Unifill’ development team to develop the world’s first glass prefilled drug delivery device with integrated auto retract safety feature. This technology was successfully licensed to Sanofi Aventis. Previously, John led the New Product Implementation Group at ResMed, where he managed the design and commercialization of the ground-breaking Mirage Swift mask. In addition to his commercial experience, John has an Honours Degree in Mechanical Engineering from the University of Liverpool, a Master’s Degree in Systems Engineering from Queen’s University Belfast, and an Executive MBA from the University of Sydney, where he was awarded the Business School’s inaugural ‘Excellence in Leadership’ scholarship.

Will Souter

Chief Financial Officer

Experienced senior finance executive, lawyer and investment banker. Most recently Will was Chief Financial Officer for property and construction tech company, Verton Technologies. Previously Executive Director at RFC Ambrian where for 11 years he worked closely with companies on fundraising, public markets listings and M&A. Prior to RFC, Will was a Director at PwC over a 10 year period in London and Sydney, and worked at Minter Ellison Lawyers. Graduate of the AICD, admitted to the Supreme Court of NSW. He holds a Bachelor of Laws, and a Bachelor of Commerce from the University of Adelaide.

Mark Smith

Chief Operating Officer

Mark Smith joined Atomo in 2019 as COO, having previously assisted the company in supply chain development. Mark was co-founder and CEO of a global manufacturing and engineering business, with operations in the UK, China and North America. Highly experienced in managing international supply chains, operations and logistics, he established a Wholly Owned Foreign Entity in Shenzhen in 2003. He oversaw the sale of the business to a listed US corporation in 2013 and continued as CEO until 2016. Mark has a BA Honours degree in Business Studies from the University of Portsmouth.

Board of Directors

John Keith

Non-Executive Chair

John is the Managing Director of BNP Paribas. Prior to that, he led management and coverage roles for Nomura Securities in Sydney and Hong Kong. John also serves as a Director of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation.

Dr. Curt LaBelle

Non-Executive Director

Dr. LaBelle has been actively involved in the healthcare industry for 20 years, both operationally and as an investor. He is the Managing Partner at the Global Health Investment Fund, a social impact investment fund, which manages approximately US$108 million backed by the Gates Foundation, JP Morgan and others. He also serves as a director on the boards of Alydia Health, Atticus Medical and Eyenovia. Prior to joining GHIF, Dr. LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He also served as chair on the boards of Exagen Inc. (NASDAQ:XGN) and Impulse Monitoring (acquired by Nuvasive) and as a director on the boards of Sirion Therapeutics, SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen).

Dr. Paul Kasian

Non-Executive Director

Chair of IODM Limited. Non-Executive Director of Eco Systems Ltd (ASX:ESL). Previously Chair and CEO of Genetic Technologies Limited. PhD in Microbiology and MBA, both from the University of Melbourne, and GAICD. Former Chief Investment Officer and Head of Global Financials at HSBC Asset Management; Founding Director of Accordius; Founding Director of Wallara Asset Management.

Deborah J. Neff

Non-Executive Director

A veteran of the life sciences industry building market-leading global businesses. As principal of DJN Consulting, LLC. based in the San Francisco Bay Area, Deborah currently works with several privately held healthcare startup companies providing strategic business advice to and mentoring the executive management team. Previously CEO of Evanostics, LLC. and Pathwork Diagnostics Inc., and COO at Complete Genomics Inc., following a 15-year career with Becton Dickinson, Inc. where she last served as President of BDBiosciences, a major global business unit of the company. Former non-executive director of Bio-Rad, Inc., ForteBio, Inc. (acquired by Pall Corp) and AMO Inc., (acquired by Abbott). Deborah served as a board member and executive advisor for Galt Inc., and Vortex Biosciences Inc. She is an Executive Trustee of the UCDavis Foundation Board and also chairs the College of Biological Sciences Dean’s Leadership Council at the University.

Work With Us

Atomo is a fast-growing dynamic company with tremendous opportunities for people interested in revolutionizing healthcare through rapid point-of-care diagnostics.

We’re looking for energetic, creative, entrepreneurial people who have a keen interest in using technology to make the world a better place.

If you would like to join our team, please email careers@atomodiagnostics.com.

Re-imagining diagnostics